NFKB1 and hyperuricemia: In murine models, LLY-606 attenuates hyperuricemia-induced inflammation by inhibiting the TLR4/MyD88/NF-κB axis, reducing pro-inflammatory cytokine release and modulating the gut microbiota (Shi et al., 2023).